Navigation Links
Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
Date:6/23/2009

CHARLOTTESVILLE, Virginia, June 23 /PRNewswire/ -- Biovista Inc. today announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant decrease of epileptic activity in mice pre-treated with Kainic acid.

"We are pleased with these initial results that confirm the predicted efficacy of BVA-601 and encourage us to further test and develop this compound in a disease area where there is a need for new, patient-friendly therapies," said Aris Persidis, Ph.D., President of Biovista. "This successful repositioning builds on our previously reported success with BVA-101 in multiple sclerosis, expanding our CNS portfolio. At the present time we are exploring all options available to us, including the further co-development with a pharmaceutical company and the licensing of the IP to a generics company," added Dr. Persidis.

For a non-confidential information pack on BVA-601, contact Biovista at info@biovista.com.

About Biovista's BVA-601 trial in the Kainic acid model of epilepsy

Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures may be transient signs and/or symptoms due to abnormal, excessive or synchronous neuronal activity in the brain. Epilepsy is one of the world's oldest recognized conditions, affecting around 50 million people worldwide. Fear, discrimination and social stigma have surrounded epilepsy for centuries. Some of the stigma continues today in many countries impacting the quality of life of people with the
'/>"/>

SOURCE Biovista Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Dragon Pharma Announces Results of 2009 Annual General Meeting
4. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
5. Isolagen, Inc. Announces Receipt of Interim Order from Bankruptcy Court Approving DIP Motion
6. Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
7. Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities
8. Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center
9. Shamir Optical Industry Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website
10. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
11. Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 6, 2015  Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company ... , Viveve,s Chief Executive Officer, and Scott Durbin , ... July 9, 2015. , , , DATE:    ... , , TIME:     , , , 12:15 PM ... , http://tinyurl.com/viveve   ,    ...
(Date:7/3/2015)... McKinney, Texas (PRWEB) , ... ... ... a biotechnology company providing industry-leading products for use in applications such as ... reduction in wastewater treatment plants and restaurant kitchen settings, announced today that ...
(Date:7/3/2015)... WIEN , July 3, 2015 /PRNewswire/ ... fram till 22 september 2015 på  http://www.openinnovationinscience.at ... Open Innovation in Science" som hålls i ... Enligt en färsk undersökning med internationella forskare ... Gesellschaft (LBG) är hälsovetenskapens två största utmaningar ...
(Date:7/2/2015)... ... ... in countless labs for decades. In the past, people had to go to a ... a daunting and tiring process looking at endless data tables and charts. Often time’s, ... catalog structure. , Now thanks to FireflySci, scientists are throwing away those old books and ...
Breaking Biology Technology:Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3DryLet to Highlight Benefits of Patented ManureMagic™ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3New Cuvette E-Commerce Website Launched by FireflySci 2
... identified, search engines are leading the way for consumers ... related to the efficacy of these search engines, among ... soon and why could this happen? , ,If search ... todays search results, which often include a great deal ...
... mentioned my first law of softwareany mildly successful software program ... operating system. Youve seen it. The e-mail system that gets ... in version three and so on. The ERP system that ... for this kind of behavior is the browser. , ,So ...
... campaign season, and you've been poked and prodded by television ... John Kerry drank a beer at your neighborhood bar and ... Dick Cheney was spotted more in Wisconsin in 2004 than ... years. John Edwards has been in the state so often ...
Cached Biology Technology:When search engines collide 2When search engines collide 3When search engines collide 4The first law of software 2The first law of software 3Twenty ways you can tell this campaign has finally pushed you over the edge 2
(Date:6/24/2015)... YORK , June 24, 2015 This ... market, over the next six years. It contains an ... the industry, along with their impact from the short, ... It also discusses the industry, market, and technology trends ... that the need of concerned authorities to efficiently manage ...
(Date:6/23/2015)... DUBLIN , June 22, 2015 ... has announced the addition of the "Body-Worn ... Share, Growth, Trends and Forecast 2014 - 2020" ... report offers strategic analysis of the global body-worn ... market has been segmented on the basis of ...
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 /PRNewswire/ ...   Produktlinie mit DNA-Tests verbessert den Analyseprozess und senkt ... ; Frankfurt Prime Standard: QIA) hat heute in den ... Investigator ® für die ... neuen Kits zur Erstellung genetischer Fingerabdrücke bieten eine integrierte ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
... such as schizophrenia, major depression and cancer are ... dysfunctional genes. A novel computational biology method developed ... PhD, http://www.njit.edu/news/2008/2008-367.php , associate professor in NJIT,s ... a way to uncover the critical genes responsible ...
... WEST LAFAYETTE, Ind. Although research has linked inbreeding ... of animals, a new study finds it plays no ... Purdue University researchers recently examined 2,000 adult and ... deformities, mainly consisting of missing, extra or dwarfed digits ...
... NEW YORK, NY (October 28, 2008) The first ... exploring the role of hospital touch surfaces in the ... researchers reported their findings in a poster session at ... in Washington, D.C. on Tuesday, October 28. The ...
Cached Biology News:NJIT professor finds engineering technique to identify disease-causing genes 2Study rules out inbreeding as cause of amphibian deformities 2
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
...
... Antigen peptide transporter 2 ... (Peptide transporter PSF2) (Peptide ... (Peptide transporter involved in ... Antigen: ...
... Recognizes Nabeta2. The epitope specific ... in any other known proteins.,SPECIES ... to work on human because ... conserved (17/19 residues). Reactivity with ...
Biology Products: